Valneva's market success hopes dwindle after disappointing Covid-19 booster data
The company’s candidate has failed as a booster option for Comirnaty-primed people, and Valneva thus resorts to create an Astrazeneca-exclusive booster instead.
by christian bundgaard, translated by daniel pedersen
With “only a marginally increased neutralizing antibody response,” Valneva can likely wave goodbye to any hopes of seizing big market shares in a competitive market for Covid-19 booster shots, writes industry media Fierce Biotech.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Valneva plunges after Europe slashes Covid-19 vaccine order
For subscribers
